High-Dose Yttrium-90 Resin Microspheres Improve Hepatocellular Carcinoma Response

Refining Locoregional Control in Hepatocellular Carcinoma

Hepatocellular carcinoma remains a leading cause of cancer-related mortality worldwide, frequently presenting at stages where curative resection or transplantation is no longer feasible [1, 2]. For these patients, transarterial radioembolization using Yttrium-90 microspheres serves as a critical locoregional intervention, often providing superior time-to-progression compared to conventional chemoembolization [3, 4]. While the safety profile of radioembolization is well-established, achieving a complete radiological response remains a primary clinical objective to improve long-term outcomes and facilitate potential downstaging [5, 6]. Current guidelines emphasize the importance of personalized dosimetry to optimize therapeutic efficacy, yet the precise mean absorbed dose required to ensure a predictable tumor response has remained a subject of debate [7, 8]. A recent retrospective study now offers specific, evidence-based radiation thresholds for resin microspheres, providing clinicians with concrete targets to optimize tumor response without compromising patient safety.

Retrospective Analysis of Dosimetry Thresholds

The researchers conducted a retrospective analysis of patients with hepatocellular carcinoma who were eligible for transarterial radioembolization using Yttrium-90 resin microspheres. This multicenter study, spanning from January 2020 to May 2024, included a cohort of 64 patients treated at two specialized centers. The study population was predominantly male, consisting of 54 men, with a mean age of 71.3 ± 9.6 years. By evaluating 76 distinct lesions, the authors sought to establish a clearer relationship between the radiation dose delivered to the tumor and the subsequent clinical response. The baseline tumor burden in this cohort was substantial, characterized by a mean tumor diameter of 55.2 ± 31.8 mm. Clinicians monitored these patients over a median follow-up period of 15.0 months (interquartile range 8.0 to 24.3 months). To assess treatment efficacy, the researchers utilized contrast-enhanced computed tomography scans at 3 and 6 months post-procedure. They applied the modified Response Evaluation Criteria in Solid Tumors (mRECIST), a standardized framework that measures treatment response in liver cancer by focusing on viable, contrast-enhancing tissue rather than total lesion size. This rigorous follow-up allowed for the precise calculation of the tumor-mean absorbed dose, representing the average amount of radiation energy absorbed by the tumor mass. For practicing oncologists and interventional radiologists, establishing this baseline is crucial for tailoring radioactive doses to individual patient anatomy.

Defining the Dose-Response Relationship

To determine the efficacy of the intervention, the researchers evaluated multiple clinical endpoints, including the objective response rate on the target lesion, complete response, overall response, time-to-local progression, and time-to-progression. To identify the most effective radiation levels, the authors employed receiver operating characteristic analysis (a statistical method used to determine the optimal cut-off values for a predictive variable) to establish the ideal tumor-mean absorbed dose at the 3-month follow-up. The study identified a specific tumor-mean absorbed dose threshold of 296.74 Gy as the primary predictor for an objective response. At this dose level, the treatment achieved a specificity of 100% and a positive predictive value of 100%, indicating that every lesion receiving this minimum dose showed a significant reduction in viable tumor volume. For clinicians targeting total tumor eradication, the data suggested a higher intensity requirement. The researchers found that a tumor-mean absorbed dose exceeding 435.11 Gy predicts a complete response. Remarkably, all hepatocellular carcinoma lesions treated with a dose greater than 435.11 Gy achieved a complete response at the 3-month assessment point. The statistical validity of these dose thresholds was confirmed through multiple analytical methods, including Fischer’s test to compare objective response rates and the Kaplan-Meier method to analyze survival outcomes (a technique that estimates the proportion of patients reaching specific clinical endpoints over time). Additionally, Cox regression was utilized for both uni- and multivariable analyses to model the time until disease progression while accounting for multiple clinical variables. These analyses reinforced the finding that the tumor-mean absorbed dose is a critical independent factor in determining local tumor control, giving interventional radiologists a clear numerical target during procedural planning.

Clinical Outcomes and Safety Profile

The longitudinal assessment of treatment efficacy revealed high rates of local tumor control when specific dosimetry thresholds were met. At the 3-month follow-up assessment, complete response on the target lesion was achieved in 42 lesions, representing more than half of the 76 lesions evaluated in the study. These radiological outcomes translated into durable clinical metrics, with the researchers reporting a mean time-to-local progression of 27.6 ± 2.5 months. Furthermore, the cohort demonstrated a mean overall survival of 36.2 ± 2.9 months, suggesting that the localized control achieved through optimized transarterial radioembolization contributes to extended survival in patients with hepatocellular carcinoma. The data underscored a clear divergence in outcomes based on the radiation dose delivered to the tumor. Patients treated with doses equal to or lower than the 296.74 Gy threshold had a significantly shorter time-to-local progression compared to those receiving higher doses (log-rank p = 0.001). This statistical difference highlights the clinical necessity of reaching the identified dose threshold to prevent early recurrence. Critically, the escalation of radiation intensity did not come at the cost of patient safety. The researchers found that a tumor-mean absorbed dose greater than 296.74 Gy did not increase the risk of complications. For practicing physicians, these findings confirm that personalized dosimetry can safely push radiation doses above standard guideline indications, maximizing the chance of complete tumor necrosis while maintaining an acceptable safety profile.

References

1. Moris D, Martinino A, Schiltz S, et al. Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians. CA A Cancer Journal for Clinicians. 2025. doi:10.3322/caac.70018

2. Wen N, Cai Y, Li F, et al. The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. BioScience Trends. 2022. doi:10.5582/bst.2022.01061

3. Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: A systematic review and meta-analysis.. World journal of hepatology. 2016. doi:10.4254/wjh.v8.i18.770

4. Dhondt E, Lambert B, Hermie L, et al. ⁹⁰Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial. Radiology. 2022. doi:10.1148/radiol.211806

5. Lin H, Tan Q. Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.. Frontiers in nuclear medicine. 2026. doi:10.3389/fnume.2026.1784215

6. Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis. Liver Transplantation. 2015. doi:10.1002/lt.24169

7. Roosen J, Klaassen NJM, Gotby LELW, et al. To 1000 Gy and back again: a systematic review on dose-response evaluation in selective internal radiation therapy for primary and secondary liver cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2021. doi:10.1007/s00259-021-05340-0

8. Weber M, Lam MGEH, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. European Journal of Nuclear Medicine and Molecular Imaging. 2022. doi:10.1007/s00259-021-05600-z